DOJ: Pharma Company Indivior Lied About Opioid Treatment Drug, Led Addicts to Overprescribing Doctors
Indivior allegedly established a hotline to refer addicts to doctors who were prescribing Suboxone Film.

Spencer Platt/Getty
The Justice Department charged pharmaceutical company Indivior with making false statements about its opioid addiction treatment drug and leading opioid addicts to doctors who were prescribing their potent drug under “suspect circumstances.” According to the indictment and a DOJ press release, the company engaged in a scheme to increase the sales of Suboxone Film by marketing the drug as “safer” and “less abusable” than other opioid addiction treatment drugs without any evidence to back up those claims. The company also allegedly established a hotline for opioid addicts that led them to doctors who Indivior knew were prescribing high doses of Suboxone Film to more people than legally permitted and in a “careless and clinically unwarranted manner.” DOJ alleges that Indivior’s practices caused “thousands” of opioid abusers to become addicted to Suboxone Film, incurring a “substantial cost to the government,” as Suboxone Film was covered by state Medicaid programs. The indictment states the company has been charged with “one count of health care fraud, four counts of mail fraud, and twenty-two counts of wire fraud.”
The company released a statement and a list of rebuttals of the DOJ’s allegations on Monday night, saying the indictment was an effort to “pursue self-serving headlines” and that it would “vigorously” contest the case in court. “We are extremely disappointed in this action by the Justice Department, which is wholly unsupported by either the facts or the law,” the company said.
Register below to read this article for free or subscribe
to unlock unlimited access to The Daily Beast.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Already have an account? Sign In
Looks like you already have a subscription!
You're all set!
Thanks for subscribing.